ISDA

Deposition Date 2011-11-28

Release Date 2012-01-25

Last Version Date 2024-02-28

Entry Detail

PDB ID:

3UUO

Keywords:

HYDROLASE/HYDROLASE INHIBITOR

Title:

The discovery of potent, selectivity, and orally bioavailable pyrozoloquinolines as PDE10 inhibitors for the treatment of Schizophrenia

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.11 Å

R-Value Free:

0.22

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
Gene (Uniprot):PDE10A
Chain IDs:A, B
Chain Length:337
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q9Y233 EC:3.1.4.17

Ligand Molecules

0CV

PO4

Primary Citation

The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia.

Ho, G.D, Yang, S.W, Smotryski, J, Bercovici, A, Nechuta, T, Smith, E.M, McElroy, W, Tan, Z, Tulshian, D, McKittrick, B, Greenlee, W.J, Hruza, A, Xiao, L, Rindgen, D, Mullins, D, Guzzi, M, Zhang, X, Bleickardt, C, Hodgson, R.Show

Bioorg.Med.Chem.Lett. 22 1019 1022 (2012)

PMID: 22222034 DOI: 10.1016/j.bmcl.2011.11.127

Abstact

High-throughput screening identified a series of pyrazoloquinolines as PDE10A inhibitors. The SAR development led to the discovery of compound 27 as a potent, selective, and orally active PDE10A inhibitor. Compound 27 inhibits MK-801 induced hyperactivity at 3mg/kg with an ED(50) of 4mg/kg and displays a ∼6-fold separation between the ED(50) for inhibition of MK-801 induced hyperactivity and hypolocomotion in rats.

Legend

Protein

Chemical

Disease

Primary Citation of related structures